Rivaroxaban 99% Pharma Pure Powder Knee Replacement Surgery 366789-02-8

Product Description

 Rivaroxaban 99% knee replacement surgery Cas366789-02-8 API manufacturer lowest price with top quality ! 

product Name	Rivaroxaban
Synonyms	5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide; Rivaroxaban intermediates; 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide; rivaroxban
Molecular Formula	C19H18ClN3O5S
Molecular Weight	435.8813
InChI	InChI=1/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
CAS Registry Number	366789-02-8
Molecular Structure
Density	1.46g/cm3
Boiling point	732.609°C at 760 mmHg
Refractive index	1.633
Flash point	396.868°C
Vapour Pressur	0mmHg at 25°C

A. Early discontinuation of Rivaroxaban will increase the risk of thromboembolic events:

Early discontinuation of any oral anticoagulants, including rivaroxaban, increases the risk of thromboembolic events. To reduce this risk, another anticoagulant should be considered if early discontinuation of rivaroxaban is necessary for reasons other than pathological bleeding or completed treatment.

B. Spinal/epidural hematoma:

Spinal/epidural hematoma has occurred in patients treated with rivaroxaban during epidural anesthesia or spinal tap. These haematomas can cause long-term or permanent paralysis. These risks need to be considered when scheduling patients for spinal surgery. Factors that may increase the risk of epidural or spinal hematoma in these patients include: use of indwelling catheters; Concurrent use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants; History of traumatic or repeated epidural or spinal puncture spinal deformity or spinal surgery. The optimal interval between rivaroxaban dosing and intraspinal surgery is not known (see "precautions" and "adverse reactions").

Patients should be closely monitored for signs and symptoms of neurological impairment. If neurological impairment is found, emergency treatment is required. For patients who have received or will receive anticoagulant therapy to prevent thrombosis, an assessment of the benefits and risks should be performed before epidural anesthesia or spinal tap (see [Caution] Spinal tap/epidural anesthesia).

ingredients

The main ingredient of this product is rivaroxaban.

Chemical Name:

5 - chloro - n - ({(5 s) - 2 - oxygen - 3 - [4 - (3 - oxygen - 4 - morpholine) phenyl] - 1, 3 - azole alkane - 5 - base} methyl) - 2 - thiophene - carboxy amide

Chemical structure formula:

 

Rivaroxaban tablets

Molecular formula: CHClNOS

Molecular weight: 435.89

character

10mg: Red film tablet.

15mg: Red film tablet.

20mg: This product is brownish red film tablet.

indications

1. To prevent venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery.

2. It is used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. Adult patients with NVAF with one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, or a history of TRANSIENT ischemic attack) to reduce the risk of stroke and systemic embolism.

specifications

(1) 10mg (2) 15mg (3)20mg

Usage.

Rivaroxaban administration:

Oral.

Rivaroxaban 10mg can be taken with food or alone.

Rivaroxaban 15mg or 20mg tablets should be taken with food.

Prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery

The recommended dose of rivaroxaban is 10 mg orally, once daily. If the wound has stopped bleeding, the first dose should be given between 6 and 10 hours after surgery.

For patients undergoing major hip surgery, the recommended course of treatment is 35 days.

For patients undergoing major knee surgery, the recommended treatment course is 12 days.

In the event of a missed dose, patients should take rivaroxaban immediately and continue to take it daily the next day.

Treat DVT and reduce the risk of acute DVT recurrence and PE

The initial recommended dose for acute DVT is 15mg twice daily for the first three weeks, followed by 20mg once daily for maintenance and to reduce the risk of recurrent PE for DVT, as shown in table 1.

Table 1 Administration regimen of Rivaroxaban tablets for DVT

 

Rivaroxaban tablets

The duration of treatment should be determined on an individual basis after careful assessment of benefit and risk of bleeding. Short-term treatment (3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilization) and long-term treatment should be based on permanent risk factors or idiopathic DVT. Experience with rivaroxaban beyond 12 months is insufficient for this indication.

Patients should take rivaroxaban immediately to ensure a daily dose of 30mg rivaroxaban if missed doses occur during the 15mg twin-daily treatment period (days 1-21). In this case two 15mg tablets may be taken at a time. Thereafter, the usual twice-daily dose of 15mg should be continued as recommended.

If missed dosing occurs during the 20mg once-daily treatment period (22nd day and beyond), patients should take rivaroxaban immediately and continue to receive once-daily dosing at the recommended dose. The dose should not be doubled in one day to make up for missed doses.

To reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation

The recommended dose is 20mg once daily, which is also the maximum recommended dose for low body weight and advanced age (> 75 years), physicians may use 15mg once daily according to the patient's condition.

In cases where the benefits of rivaroxaban in preventing stroke and systemic embolism outweigh the risk of bleeding, long-term treatment should be undertaken (see [Precautions]).

In the event of missed dosing, patients should take rivaroxaban immediately and continue to receive once-daily dosing the next day. The dose should not be doubled in one day to make up for missed doses.

Withdrawal due to surgery or other intervention

If anticoagulant therapy must be discontinued to reduce the risk of bleeding during surgery or other interventions, rivaroxaban must be discontinued at least 24 hours prior to intervention to reduce the risk of bleeding. Given the rapid onset of action, rivaroxaban should be re-used immediately after surgery or other intervention procedures as soon as sufficient hemostasis is determined. Consider non-oral anticoagulants if oral medications are not available during or after surgical intervention.

To select

For patients who cannot swallow the whole tablet, rivaroxaban tablets 10mg, 15mg, or 20mg May be crushed and mixed with applesauce before administration. Rivaroxaban 15mg or 20mg crushed tablets should be taken immediately after administration.

Administration via nasogastric tube (NG) or gastric feeding tube: Rivaroxaban tablets 10mg, 15mg, or 20mg can also be administered via nasogastric tube or gastric feeding tube after the gastric tube position has been determined in the stomach, crushed and mixed with 50mL water to form a suspension. Because absorption of rivaroxaban depends on the site of drug release, administration in the distal stomach should be avoided, as it may decrease absorption and thus reduce drug exposure. Food should be given through enteral nutrition immediately after the administration of crushed rivaroxaban 15mg or 20mg tablets.

Crushed 10mg, 15mg or 20mg rivaroxaban tablets are stable in water or applesauce for up to 4 hours. In vitro compatibility studies showed that rivaroxaban was not adsorbed from the suspension to PVC or silicone nasogastric tubes.

Switch from vitamin K antagonist (VKA) to rivaroxaban

For patients with reduced risk of stroke and systemic embolism, VKA should be discontinued and rivaroxaban therapy should be initiated at an international standardized ratio (INR) of 3.0 or less.

For patients treated with DVT and reducing the risk of DVT recurrence and PE after acute DVT, VKA should be discontinued and rivaroxaban therapy should be initiated when the international standardized ratio (INR) ≤2.5.

When patients were switched from VKA to rivaroxaban, the INR value would show a false increase, but it is not an effective indicator to measure the anticoagulant activity of rivaroxaban. Therefore, INR is not recommended to evaluate the anticoagulant activity of rivaroxaban.

From rivaroxaban to vitamin K antagonist (VKA)

Inadequate anticoagulation may occur during the conversion of Rivaroxaban to VKA. Conversion to any other anticoagulant should ensure continued adequate anticoagulant action. It should be noted that rivaroxaban can increase INR.

For patients switching from Rivaroxaban to VKA, a combination of VKA and rivaroxaban should be used until INR≥2.0. The standard starting dose of VKA should be used for the first two days of the transition period, followed by adjustment of the VKA dose based on INR findings. When patients are given rivaroxaban in combination with VKA, INR should be measured 24 hours after rivaroxaban administration and before the next rivaroxaban administration. Reliable INR values can be detected after discontinuation of rivaroxaban at least 24 hours after last administration.

Conversion from non-oral anticoagulants to rivaroxaban

For patients who are receiving non-oral anticoagulants, rivaroxaban should be started 0-2 hours before the next scheduled time of administration for those who are not on continuous administration (e.g., subcutaneous low-molecular-weight heparin) and when discontinued for those who are on continuous administration (e.g., regular intravenous heparin).

Conversion from Rivaroxaban to non-oral anticoagulant

Rivaroxaban was discontinued and the first dose of non-oral anticoagulant was administered at the next scheduled dosing time of Rivaroxaban.

Special populations

Patients with impaired renal function

Rivaroxaban dose need not be adjusted in patients with mild renal impairment (creatinine clearance CrCl: 50-80 ml /min).

For patients with moderate (creatinine clearance 30-49mL/min) or severe renal impairment (creatinine clearance 15-29 ml /min), the following dosages are recommended:

- For adults undergoing elective hip or knee replacement to prevent venous thrombosis, moderate renal impairment (creatinine clearance 30-49 ml /min) does not require dose adjustment. Avoid CrCl< Rivaroxaban was used in patients at 30mL/min.

- to treat the risk of DVT recurrence and PE after DVT: for the first three weeks, patients should receive 15mg twice daily. Thereafter, the recommended dose is 20mg once daily. If the patient's risk of bleeding is assessed to exceed the risk of DVT recurrence and PE, consideration must be given to reducing the dose from 20mg once daily to 15mg once daily. The recommendation to use 15mg is based on the PK model and there are no clinical studies. In CrCl< Rivaroxaban should be avoided in patients at 30mL/min.

- 15mg once daily is recommended for adult patients with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism. Creatinine clearance is not recommended. Patients at 15mL/min were given rivaroxaban.

Patients with impaired liver function

Rivaroxaban is contraindicated in patients with liver disease with coagulation abnormalities and at risk of clinically relevant bleeding, including cirrhosis with Child Pugh grade B and C.

gender

Dose adjustment is not required.

Adverse reactions

The following adverse events are also discussed in other sections of this manual: An increased risk of stroke after early discontinuation in patients with nonvalvular atrial fibrillation

Increased risk of stroke after early discontinuation in patients with nonvalvular atrial fibrillation (see [warnings] and [Cautions])

· Bleeding risk (see [Precautions])

· Spinal/epidural hematoma (see [Warning] and Precautions])

clinical trials

Due to the different conditions under which clinical trials are conducted, the incidence of adverse reactions observed in a clinical trial of one drug cannot be directly compared to the incidence observed in a clinical trial of another drug and may not reflect the incidence observed in clinical practice.

During clinical development for the approved indication, 16,326 patients received rivaroxaban. Included 7111 patients who received rivaroxaban 15mg or 20mg orally, once daily, for an average of 1 month (5558 for 12 months and 2512 for 24 months) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (ROCKET AF); 4728 patients received rivaroxaban 15mg orally twice daily for 3 weeks followed by 20mg orally once daily (EINSTEIN DVT, EINSTEIN PE) or 20mg orally, Patients treated once a day (EINSTEIN Extension Study) for DVT and PE, and to reduce the risk of DVT recurrence and PE; 4487 patients who received rivaroxaban 10mg orally, once daily to prevent DVT after hip or knee replacement surgery (RECORD 1-3).

Hemorrhage:

Bleeding is the most common adverse reaction with rivaroxaban (see [Precautions]).

To reduce the risk of stroke and systemic embolism in patients with nonvalvular fibrillation.

In the ROCKET AF trial, the most common adverse events associated with permanent withdrawal were bleeding events, occurring in 4.3% of patients with rivaroxaban and 3.1% of patients with warfarin. The incidence of discontinuation due to non-bleeding adverse events was similar in both treatment groups. Table 2 shows the number of patients who experienced various types of bleeding events in the ROCKET AF study.

Table 2. Bleeding events in ROCKET AF clinical trial studies *

Why Choose Us?

 

1. High-concentration products, strictly control the quality.
2. Reasonable and flexible price matched with high quality.
3. Spot samples can be shipped quickly after payment, saving time for receiving goods.
4.Full experience of large numbers containers loading in Chinese sea port.
5. Safe raw materials from China.
6. Have professional customs clearance capabilities and the best after-sales service.

 

Our Service

1.Cooperate with research institutions, we strictly control the process from raw material to finished product.
2.The customer comes first, we provide reasonable price, high quality product and prompt shipment.
3.We can send the goods to your delivery address directly. It is relatively safe and fast.
4.Quick and clear response to customers questions.
5.We could make our price discount if you place a substantial order with us.
6.Products can be packaged according to customer requirements.

F.A.Q1:Can I get some samples before bulk order?
Most products provide free samples, but the shipping cost be paid by customers.

 

2: What's your MOQ?

For the high value product, our MOQ starts from 10g,100g and 1kg.

 

3: Which kind of payment terms do you accept?

PI will be sent first after confirmation of order,enclosed our bank information.Payment by T/T, Western Union, L/C, Alibaba trade assurance, Cashapp,Moneygram or Bitcoin.

 

4.How to place an order?

You can contact me through Trademanager, WhatsApp, Skype Online and other contact methods, tell me the product and quantity you need, and then we will give you a quote. If you choose one of the above payment methods, we will arrange the delivery for you.

 

5:How about your delivery time?

A: Generally, it will take 3 to 5 days after receiving your advance payment.

 

6: How do you treat quality complaint?

A:First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.